Attached please find our March 2014 published manuscript: “Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance“.
The high prevalence of MYD88 L265P in lymphoplasmacytic cells from bone marrow samples of IgM MGUS and WM patients prompted us to examine whether peripheral blood cells could be used as a source for demonstrating presence of this somatic mutation.
The findings suggest that peripheral blood AS–PCR testing for MYD88 L265P may in the appropriate clinical context be used to establish the diagnosis of WM and help provide a convenient, noninvasive and inexpensive method to (1) establish the diagnosis of WM, (2) follow changes in underlying disease burden, and (3) possibly eliminate the determining method of a bone marrow biopsy.
Dana Farber Cancer Institute, Harvard Medical School
Bing Center for Waldenstrom’s Macroglobulinemia